Adelaide, Australia | North Carolina, USA – Avance Clinical, the award-winning Australian and North American market leading CRO for biotechs, has again been recognized for its contribution to International Health in the 61st Australian Export Awards 2023.
The Australian Export Awards ceremony will be held on 30 November in Canberra at Parliament House.
CEO Yvonne Lungershausen said, “Winning an Australian Export Award would be an incredible honour in recognition of Avance Clinical’s rapid growth, high quality service delivery and continued innovation in the clinical trials sector.”
Avance Clinical’s primary focus is to find the best solutions for biotech’s drug development programs by offering deep scientific knowledge and execution experience. The companies agile and compliance-focused approach ensures the efficient access of medicines to patients with unmet needs.
“We pride ourselves on being nimble and adaptive while focusing on operating to the highest standards of quality and compliance required by global regulatory agencies to ensure acceptance of data and subsequent drug approvals,” Ms Lungershausen said.
Avance Clinical has experienced significant growth since being established in 2019, with its primary market being the United States, followed by Asia and Europe. Recently, the company established a North Carolina office, and a biometrics hub in Bangalore, India, to support its global biometrics team.
“Avance Clinical now offers a specialised service, the GlobalReady program, which takes clients into Australia to commence their early phase clinical trials and reaps the benefits of the R&D Tax Rebate, and then seamlessly transitions them into the US for their later phase trials through Avance Clinical’s North American operations team,” she said.
About Avance Clinical
Avance Clinical is a full-service CRO for biotechs with a proven track-record for delivering clinical excellence in Australia, New Zealand, India and North America. As the largest premium full-service CRO in Australia and North America dedicated to biotechs, Avance Clinical specializes in delivering top-tier clinical trials that yield globally accepted data.
Award-winning CRO for Biotechs
Avance Clinical has been recognised for the fourth consecutive year by Frost & Sullivan in 2023, being awarded the Best Practices Customer Value Leadership for Biotech’s award, for its continuous exceptional performance.
Pre-clinical through to Phase I and Beyond
Avance Clinical offers pre-clinical consultancy services with their experienced ClinicReady team right through to Phase I and beyond clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes that are available in Australia. With experience across more than 110 therapeutic indications, Avance Clinical can deliver world-class, high-quality, internationally accepted data suitable for all major regulators, including FDA and EMA.
Avance Clinical uses state-of-the-art technology and gold-standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, Zelta, Veeva and Medrio are just some of Avance Clinical’s technology partners.